


## Hydroxyfasudil

Cat. No.:	HY-13911
CAS No.:	105628-72-6
Molecular Formula:	C <sub>14</sub> H <sub>17</sub> N <sub>3</sub> O <sub>3</sub> S
Molecular Weight:	307.37
Target:	ROCK
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 31 mg/mL (100.86 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.2534 mL	16.2670 mL	32.5341 mL
	5 mM		0.6507 mL	3.2534 mL	6.5068 mL
	10 mM		0.3253 mL	1.6267 mL	3.2534 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 0.5 mg/mL (1.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 0.5 mg/mL (1.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 0.5 mg/mL (1.63 mM); Clear solution

### BIOLOGICAL ACTIVITY

Description	Hydroxyfasudil is a ROCK inhibitor, with IC <sub>50</sub> s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively.		
IC <sub>50</sub> & Target	ROCK2 0.72 μM (IC <sub>50</sub> )	ROCK1 0.73 μM (IC <sub>50</sub> )	PKA 37 μM (IC <sub>50</sub> )
In Vitro	Hydroxyfasudil is a ROCK inhibitor, with IC <sub>50</sub> s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively. Hydroxyfasudil also		

less potently inhibits PKA, with an  $IC_{50}$  of 37  $\mu$ M, 50-fold higher than those of the ROCKs. Hydroxyfasudil increases eNOS mRNA levels, with an  $EC_{50}$  value of  $0.8 \pm 0.3$   $\mu$ M. Hydroxyfasudil (0-100  $\mu$ M) concentration-dependently increases eNOS activity and stimulates NO production in human aortic endothelial cells (HAEC). Hydroxyfasudil (10  $\mu$ M) increases the half-life of eNOS mRNA from 13 to 16 hours, but does not affect eNOS promoter activity at concentrations from 0.1 to 100  $\mu$ M<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Hydroxyfasudil (10 mg/kg, i.p.) significantly increases both the average and maximal voided volumes in SD rats. Hydroxyfasudil also significantly decreases the maximal detrusor pressure<sup>[2]</sup>. Hydroxyfasudil (3 mg/kg, i.p) inhibits hypercontractility induced by norepinephrine in spontaneously hypertensive rats (SHRs). Furthermore, Hydroxyfasudil (3, 10 mg/kg, i.p) significantly ameliorates decreased penile cGMP contents in rats<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Animal Administration <sup>[2]</sup>

Micturition behavior is studied after intraperitoneal injection of either Hydroxyfasudil (10 mg/kg) or a corresponding volume of saline. Each rat is placed in a metabolic cage containing a urine collection funnel that is placed over an electronic balance. The balance is connected to a personal computer via a multiport controller and used to measure the cumulative weight of the collected urine. Every 150 s during a continuous 24-h period, the computer samples and records the data for the micturition frequency and volumes. The micturition reflex parameters that are collected include: urine volume per micturition, maximal micturition volume, micturition frequency, and total urine output in the Hydroxyfasudil- or vehicle-treated animals. Each monitoring session started at 18.00 hours. Prior to being placed in the metabolic cage at the start of each experimental period, the animals receive either a single injection of Hydroxyfasudil (10 mg/kg) dissolved in saline or an injection of saline without the inhibitor<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Nat Commun. 2021 Jul 22;12(1):4457.
- Int Immunopharmacol. 2023 Aug 22;124(Pt A):110791.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Rikitake Y, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005 Oct;36(10):2251-7. Epub 2005 Sep 1.
- [2]. Masago T, et al. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model. Int J Urol. 2009 Oct;16(10):842-7.
- [3]. Saito M, et al. Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat. Pharmacol Res. 2012 Oct;66(4):325-31.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA